Yes, but keep the medication in its original packaging, carry a copy of the prescription, and be aware of the destination country’s regulations on controlled substances. The UK MHRA allows export of a three-month supply for personal use.
Colofac 135 mg tablets are typically round, white, and bear an imprint of the brand name “COLOFAC” and the dosage strength “135”. Appearance may vary slightly between manufacturers.
Both act as antispasmodics, but mebeverine (Colofac) is a synthetic agent with a defined dosing schedule, whereas peppermint oil is a botanical product often taken in enteric-coated capsules. Clinical guidelines may recommend trying peppermint oil first in mild cases before progressing to prescription options like mebeverine.
Mebeverine is not a controlled substance and does not appear on standard workplace drug screens. It should not cause a positive result for any commonly tested illicit drug.
The tablet formulation does not contain lactose as an excipient, making it generally safe for people with lactose intolerance. Always verify the full excipient list on the patient information leaflet.
Contact your prescribing clinician or pharmacy for advice. In most cases, you can simply resume the regular dosing schedule without taking an extra dose.
Mebeverine has minimal systemic cardiovascular effects. However, rare reports of arrhythmia exist; patients with known heart conditions should be monitored closely.
Mebeverine is not listed on the World Anti-Doping Agency (WADA) prohibited list, but athletes should disclose all medications to their sporting bodies to avoid inadvertent violations.
Most tablets retain potency for 2-3 years from the date of manufacture when stored as directed. The exact expiry date is printed on the packaging and should be observed.
Colofac contains the active ingredient mebeverine and is marketed in the United Kingdom as a 135 mg oral pill. Mebeverine belongs to the class of spasmolytic (antispasmodic) agents that act on smooth muscle in the gastrointestinal (GI) tract. The medication is prescription-only (Rx) and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Mebeverine’s primary action is to reduce abnormal muscle spasms in the gut without affecting normal motility. It:
These actions help relieve the abdominal pain, cramping, and urgency that characterize functional bowel disorders such as irritable bowel syndrome (IBS).
In the UK, Colofac is licensed for the symptomatic treatment of irritable bowel syndrome (IBS), specifically when abdominal pain and spasm are prominent features. The medication is not indicated for underlying inflammatory bowel disease, infections, or structural GI lesions.
Typical patients include adults who experience recurrent abdominal discomfort linked to bowel habits and who have already been evaluated to exclude organic pathology.
Current peer-reviewed evidence does not support routine off-label use of mebeverine for conditions outside of IBS. Any experimental application should be considered only under specialist supervision and within a clinical trial framework.
Mebeverine has a modest interaction profile, but caution is warranted with:
This article provides educational information about Colofac (mebeverine 135 mg) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
